



World Health  
Organization

GUIDELINES



CONSOLIDATED GUIDELINES ON  
**THE USE OF  
ANTIRETROVIRAL DRUGS  
FOR TREATING AND  
PREVENTING HIV INFECTION**

RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH

JUNE 2013



CONSOLIDATED GUIDELINES ON  
**THE USE OF  
ANTIRETROVIRAL DRUGS  
FOR TREATING AND  
PREVENTING HIV INFECTION**

RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH

JUNE 2013

## WHO Library Cataloguing-in-Publication Data

Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach June 2013.

1.HIV infections – drug therapy. 2.HIV infections – prevention and control.  
3.Anti-Retroviral agents – therapeutic use. 4.Guideline. I.World Health Organization.

ISBN 978 92 4 150572 7

(NLM classification: WC 503.2)

© **World Health Organization 2013**

All rights reserved. Publications of the World Health Organization are available on the WHO web site ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site ([http://www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Design and layout by ACW, London

Re-printed in November 2013 with changes.

# CONTENTS

Abbreviations and acronyms	11
Definition of key terms	13
Acknowledgements	17
Foreword	23
Executive summary	25
Summary of new recommendations	27
<b>1. Introduction</b>	<b>37</b>
1.1 Background and context	38
1.2 Rationale for consolidated guidelines	38
1.3 Objectives	39
1.4 Target audience	39
1.5 Scope and components	40
1.5.1 Introductory chapters	40
1.5.2 Clinical guidance	40
1.5.3 Operational and service delivery guidance	40
1.5.4 Guidance for programme managers	41
1.5.5 Monitoring and evaluation	41
<b>2. Guiding principles</b>	<b>43</b>
2.1 Contribution to global health goals	44
2.2 Public health approach	44
2.3 Strengthening health systems through innovation and learning	44
2.4 Increasing the effectiveness and efficiency of programmes	45
2.5 Promoting human rights and health equity	45
2.6 Implementation based on local context	45
<b>3. Methods and process for developing the guidelines</b>	<b>47</b>
3.1 Overview	48
3.2 Information sources	48
3.3 External participation	49
3.3.1 Guideline Development Groups and peer review process	49

3.3.2	Conflicts of interest		49
3.4	Process of formulating recommendations		50
3.5	Other methods		53
3.6	Dissemination		53
<b>4.</b>	<b>Organization of the guidelines</b>		<b>55</b>
	Continuum of care		56
4.1	Structure of presentation for new recommendations		58
4.2	Structure of presentation of selected recommendations from existing guidelines		58
4.3	How to use the guidelines for specific populations		59
4.3.1	Pregnant and breastfeeding women 		59
4.3.2	Adolescents 		61
4.3.3	Children 		63
4.3.4	Key populations 		64
<b>5.</b>	<b>Clinical guidelines across the continuum of care: HIV diagnosis and ARV drugs for HIV prevention</b>		<b>67</b>
5.1	HIV testing and counselling		68
5.1.1	Introduction		68
5.1.2	HIV testing and counselling in health facilities		69
5.1.3	Community-based HIV testing and counselling		70
5.1.4	HIV testing and counselling in specific populations 		72
5.2	HIV prevention based on ARV drugs		82
5.2.1	Oral pre-exposure oral prophylaxis		82
5.2.2	ART for prevention among serodiscordant couples		83
5.2.3	Post-exposure prophylaxis for occupational and non-occupational exposure to HIV		83
5.2.4	Combination HIV prevention		84
<b>6.</b>	<b>Clinical guidelines across the continuum of care: Linking people diagnosed with HIV infection to HIV care and treatment</b>		<b>85</b>
6.1	Introduction		86
6.2	Good practices for linkage to care		86
6.3	General care for people living with HIV		86

6.4	Preparing people living with HIV for ART	89
6.5	What to expect in the first months of ART	90
<b>7.</b>	<b>Clinical guidance across the continuum of care: Antiretroviral therapy</b>	<b>91</b>
7.1	When to start ART	92
7.1.1	When to start ART in adults and adolescents 	93
7.1.2	When to start ART in pregnant and breastfeeding women 	100
7.1.3	ARV drugs and duration of breastfeeding 	104
7.1.4	When to start ART in children 	108
7.2	What ARV regimen to start with (first-line ART)	112
7.2.1	First-line ART for adults 	113
7.2.2	First-line ART for pregnant and breastfeeding women and ARV drugs for their infants 	116
7.2.3	First-line ART for children younger than three years of age 	122
7.2.4	First-line ART for children three years and older (including adolescents) 	126
7.2.5	TB co-treatment in children 	130
7.3	Monitoring response to ART and the diagnosis of treatment failure 	132
7.3.1	Laboratory monitoring before and after initiating ART	132
7.3.2	Monitoring the response to ART and the diagnosis of treatment failure	133
7.4	Monitoring and substitutions for ARV drug toxicities 	138
7.4.1	Guiding principles	138
7.4.2	Major types of ARV toxicities	138
7.4.3	Monitoring TDF toxicity	141
7.4.4	Toxicity monitoring for other ARV drugs	142
7.4.5	Drug substitutions for ARV drug toxicity	143
7.4.6	Key ARV drug interactions	143
7.5	What ARV regimen to switch to (second-line ART)	146
7.5.1	Second-line ART for adults and adolescents 	146
7.5.2	Second-line ART for children (including adolescents) 	150
7.6	Third-line ART 	153

<b>8.</b>	<b>Clinical guidance across the continuum of care: Managing common coinfections and comorbidities</b>		<b>155</b>
8.1	Prevention, screening and management of common coinfections		156
8.1.1	Co-trimoxazole preventive therapy		156
8.1.2	Tuberculosis		158
8.1.3	Cryptococcal infection		165
8.1.4	Hepatitis B and C		166
8.1.5	Malaria		167
8.1.6	Sexually transmitted infections and cervical cancer		168
8.1.7	Vaccines for people living with HIV		169
8.2	Preventing and managing other comorbidities and chronic care for people living with HIV		170
8.2.1	Screening for and care of noncommunicable diseases		170
8.2.2	Mental health		171
8.2.3	Drug use and drug use disorders		171
8.2.4	Nutritional care and support		172
8.2.5	Palliative care: symptom management and end-of-life care		173
8.2.6	Other relevant general guidance on care		173
<b>9.</b>	<b>Guidance on operations and service delivery</b>		<b>175</b>
9.1	Introduction		176
9.2	Adherence to ART		176
9.2.1	Barriers to adherence		176
9.2.2	Interventions to optimize adherence to ART		178
9.2.3	Monitoring adherence to ART in routine programme and care settings		181

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_28140](https://www.yunbaogao.cn/report/index/report?reportId=5_28140)

